The global non-viral drug delivery market is expected to grow at a CAGR of 13.80% during the forecast period of 2025-2034, driven by growing demand for treatments tailored to individual genetic profiles across the globe.
Base Year
Historical Year
Forecast Year
The market is expanding due to increasing demand for safer and more efficient gene therapies. Non-viral systems, such as lipid nanoparticles and polymer-based carriers, offer improved safety profiles, reducing the risk of immune responses compared to viral delivery methods.
Technological advancements in nanomedicine and biodegradable carriers are driving the growth of the market. These innovations are enhancing drug stability, targeted delivery, and controlled release, particularly for complex diseases such as cancer and genetic disorders.
Rising investment in research and development, alongside the increasing prevalence of chronic diseases, is fueling market growth.
Non-viral drug delivery refers to methods that deliver therapeutic agents without using viruses to transport the drugs into cells. This approach includes techniques such as liposomes, nanoparticles, and polymer-based systems, offering a safer alternative to viral methods. It aims to enhance drug efficacy, targeting, and patient safety in treatment.
Innovative Non-viral Drug Delivery Platforms to Drive Market Growth
Increasing demand for advanced drug delivery systems and the rising prevalence of age-related diseases are propelling market growth. In February 2024, PulseSight Therapeutics SAS, a new ophthalmology biotech company, secured seed funding from Pureos Bioventures and ND Capital. The company is developing a disruptive, minimally invasive non-viral gene delivery platform targeting age-related macular diseases (AMD), including geographic atrophy. This novel approach is set to impact the non-viral drug delivery market by providing more effective treatments for conditions affecting the elderly, driving market expansion in the forecast period.
Investment in Non-viral Drug Delivery to Meet Rising Non-Viral Drug Delivery Market Demand
The rising need for more targeted treatments and breakthroughs in nanotechnology fuels market growth in non-viral drug delivery. In May 2022, Sofinnova Partners invested EUR 3.5 million in NanoPhoria, a biotech firm working on a non-viral drug delivery platform based on inorganic nanoparticles. This investment aims to advance treatments for heart failure with reduced ejection fraction (HFrEF). As the platform progresses, it is poised to have a significant impact on the global non-viral drug delivery market, offering more efficient and precise therapies, and thereby fostering market development during the forecast period.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Delivery Method
Market Breakup by Application
Market Breakup by Technology
Market Breakup by End User
Market Breakup by Region
Market Share Based on Technology to Witness Substantial Growth
Nanoparticle drug delivery systems are expected to hold the largest market share in the market. This is due to their versatility, ability to target specific cells, and high efficiency in delivering drugs, particularly for cancer and chronic diseases. Nanoparticles can encapsulate a wide range of drugs, including poorly water-soluble compounds, and protect them from degradation in the body, ensuring sustained and controlled release. Additionally, advancements in nanotechnology are enhancing their effectiveness, improving drug bioavailability, and reducing side effects, making them a preferred choice in the pharmaceutical and biopharmaceutical sectors.
North America leads the non-viral drug delivery market share, driven by its advanced healthcare infrastructure and high prevalence of chronic diseases. The region benefits from government support for healthcare advancements and the rapid adoption of cutting-edge technologies. The presence of major global biotechnology companies in the region also contributes significantly to its market share.
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Moderna, Inc., founded in 2010 and headquartered in Cambridge, Massachusetts, USA, is a biotechnology company known for its pioneering mRNA-based therapies. Moderna’s portfolio in the non-viral drug delivery market primarily focuses on mRNA vaccines and therapeutics, including its COVID-19 vaccine. The company is also exploring the use of lipid nanoparticles (LNPs) for targeted mRNA delivery, a non-viral method to transport RNA into cells, making it a key player in advancing novel drug delivery systems for various diseases.
Alnylam Pharmaceuticals, Inc., established in 2002 and headquartered in Cambridge, Massachusetts, USA, is a global leader in RNA interference (RNAi) therapeutics. Alnylam’s portfolio in the non-viral drug delivery market includes treatments that utilise lipid nanoparticle (LNP) delivery systems to deliver small interfering RNA (siRNA) to target cells. Their innovations in RNAi-based therapies are focused on treating genetic diseases, including hereditary transthyretin-mediated amyloidosis (hATTR), positioning Alnylam as a pioneer in non-viral drug delivery technologies.
Arbutus Biopharma Corporation, founded in 2002 and headquartered in Burnaby, British Columbia, Canada, is a biopharmaceutical company focused on developing therapies for viral infections. In the non-viral drug delivery market, Arbutus is exploring lipid nanoparticle (LNP) technology for targeted delivery of RNA therapeutics.
Boehringer Ingelheim International GmbH, established in 1885 and headquartered in Ingelheim, Germany, is a global pharmaceutical company focusing on human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. Boehringer Ingelheim’s portfolio in the non-viral drug delivery market includes innovations in nanoparticle-based delivery systems, such as lipid nanoparticles and polymers, for targeted drug delivery.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Ionis Pharmaceuticals, Inc., CureVac N.V., Pfizer, Inc., Precision NanoSystems Inc., Cytiva Bioscience Holding Ltd., and Silence Therapeutics plc.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Delivery Method |
|
| Breakup by Application |
|
| Breakup by Technology |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share